Skip to main content
CAPRCapricor Therapeutics, Inc.Sell4.3·$8.58
CAPR · Why this verdict

Why Capricor Therapeutics (CAPR) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Capricor is a cash-burning, single-pipeline biotech with 148.8% upside to the analyst target but missed EPS in 3 of 4 quarters, 36% short interest and a confirmed downtrend.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The business depends on one pipeline asset, Deramiocel, with donor hearts as a key supplier, flagged as 3 high-severity concentration risks.

↓Deteriorating
Bear case
Expectation
The lead program advances without a regulatory setback over 12 months.

CounterA regulatory rejection or supply constraint would eliminate most of the company's value.

Price of $9.53 sits 148.8% below the $23.71 analyst target, a reward-to-risk of 9.92 against 15.0% downside.

Tripped↓Deteriorating
Targets
Expectation
Price rises at least 50% toward the $23.71 target within 12 months.

CounterLight analyst coverage and binary pipeline outcomes mean the target is highly uncertain.

Quality scores 1.6 out of 10 with negative free cash flow, no moat and a Piotroski F-Score score of 4.4.

→Stable
Quality breakdown
Expectation
Cash burn is funded without dilution beyond 15% over 12 months.

CounterContinued losses likely require new equity raises that dilute holders.

Price is below the 200-day moving average with a -12.1% 30-day slope and short interest is 36%, with implied volatility at 644%.

↓Deteriorating
Risk breakdown
Expectation
Short interest falls below 25% and price reclaims the 200-day average.

CounterHigh short interest in a deeply oversold name can fuel a sharp squeeze on positive pipeline news.

Capricor missed EPS estimates in 3 of the last 4 reported quarters with an average surprise of -28.1%, the latest -78.59%.

↑Improving
Earnings
Expectation
EPS surprise stays above -10% in the next 2 quarters.

CounterFor a pre-revenue biotech, EPS misses mostly reflect trial spending timing rather than business failure.

Per-dimension breakdown

Value

5.0/10data confidence 50%

Quality

1.6/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio6.2
FCF quality0.0
Moat4.0
Piotroski F4.4
  • ▸Cash-burning (FCF negative)
  • ▸No competitive moat
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

4.4/10data confidence 100%
ComponentSub-score
RSI4.0
MACD9.1
OBV1.0
MA position6.0
Volume2.1
  • ▸Volume distribution (falling OBV)
  • ▸Below 200-MA, MA slope -12.0%/30d — confirmed downtrend

Sentiment

7.6/10data confidence 100%
ComponentSub-score
LLM sentiment6.4
Analyst rating6.6
Price target10.0
  • ▸Light analyst coverage (6.0) — signal dampened
  • ▸Analyst upside: 218%

Insider

5.3/10data confidence 75%
ComponentSub-score
materiality5.0
holder change5.9
notable moves5.0
  • ▸No net insider activity — $0 (0.000% of mkt cap)

Peer rank

3.0/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank0.0
growth rank5.0

Technical

3.2/10data confidence 100%
ComponentSub-score
bollinger4.0
support resistance4.8
52w position0.0
gap4.0

Risk (lower is worse)

3.7/10data confidence 100%
ComponentSub-score
short interest0.0
days to cover5.3
volatility0.0
put call4.5
implied vol0.0
max pain risk3.0
beta8.4
debt equity8.2
  • ▸High short interest justified: 36%
  • ▸High IV: 679%
  • ▸Above max pain $1
  • ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

3.9/10data confidence 100%
ComponentSub-score
erm6.5
earnings history0.0
earnings timing5.0
surprise avg0.0
news activity8.0
  • ▸Earnings concerns: 0B/3M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (6)
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_BOOST:ANALYST:0.60
  • EARNINGS_PROXIMITY:114d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • MOMENTUM:4.4<4.5
  • DEATH_CROSS:HARD_BLOCK
Warning (1)
  • ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+28.3%
Downside
15.0%
Sizing output
AVOID

SetupRecovery — Death cross but MACD improving, RSI 60

EdgeNo clear edge — No clear edge identified

SuitabilitySpeculative — Drawdown -79% (>40% off 52w high), Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Sentiment at 7.6 and asymmetric R:R of 0.00.

The strongest dimensions are Sentiment at 7.6, Insider at 5.3, and Value at 5.0; the weakest are Quality at 1.6, Peer rank at 3.0, and Technical at 3.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Large Analyst Target UpsideTripped

    Trip ifPrice falls below the stop-loss of $8.86 or the analyst target drops below $15.

  • P2Single Pipeline Concentration

    Trip ifRegulator issues a rejection of Deramiocel, dropping price more than 50% in a day.

  • P3Cash Burn Weak Quality

    Trip ifShare count increases by more than 20% from dilution.

  • P4Downtrend Heavy Short Interest

    Trip ifShort interest rises above 45% of float.

  • P5Repeated Earnings Misses

    Trip ifEPS surprise stays below -25% for 2 more consecutive quarters.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › CAPR › Why this verdict